Navigation Links
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Date:7/14/2008

MOUNTAIN VIEW, Calif., July 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine.

MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In the company's prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia, the other key measurements in treating migraine.

This randomized, double-blind, placebo-controlled Phase 3 trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine. The primary efficacy endpoints will be pain relief, and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. MAP will also evaluate earliest onset of pain relief and sustained relief to 24 and 48 hours. The multi-center efficacy trial will include approximately 850 patients, who will also be followed for 12 months in an open-label study to confirm long-term safety.

"We believe that MAP0004 has the potential to be a first-line therapy for migraine patients," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Based on our initial clinical studies, we believe that MAP0004 offers an alternative to triptans that may provide patients with the benefits of rapid onset and long-lasting pain relief, in an easy-to-use, non-invasive, at-home therapy. In our Phase 2 trials, MAP0004 was well tolerated with no effect on pulmonary function, including in asthmatic subjects."

The therapeutic agent
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  Research and Benchmarking firm, ... Medical Affairs Roundtable on Thursday, May ... virtual roundtable to discuss "Medical Affairs, Role in ... Practices, Medical Affairs Consortium provides Medical Affairs leaders ... key challenges they face. The consortium has developed ...
(Date:5/22/2015)... /CNW/ - The Taskforce representing Canada,s ... hard work that the Minister and Health Canada have put ... recognizes the needs of the thalidomide survivors, and more than ... tax free, with annual adjustments for inflation. Certain ... of $100,000 based on the severity of their disability, tax ...
(Date:5/22/2015)... , May 22, 2015  Amgen (NASDAQ: ... has commenced termination of its participation in ... AstraZeneca (LON:AZN, STO:AZN and NYSE: AZN ... in development for patients with moderate-to-severe plaque ... decision was based on events of suicidal ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... , ATLANTA, Dec. 16 Medlytix, a national healthcare ... half-billion dollar milestone - the total amount of money that ... than a half-million patients nationwide by doing a better job ... years. , "We,re proud that each of these hospitals enhanced ...
... , SOMERVILLE, N.J., Dec. 16 Ethicon, Inc., a ... a worldwide leader in surgical care, and Acclarent, Inc., a ... commercializing devices that address conditions affecting the ear, nose and ... will acquire Acclarent in an all-cash transaction for approximately $785 ...
Cached Medicine Technology:Healthcare Scoring System Allows Hospitals To Increase Charity Care 2Healthcare Scoring System Allows Hospitals To Increase Charity Care 3Healthcare Scoring System Allows Hospitals To Increase Charity Care 4Ethicon Announces Definitive Agreement to Acquire Acclarent 2Ethicon Announces Definitive Agreement to Acquire Acclarent 3Ethicon Announces Definitive Agreement to Acquire Acclarent 4
(Date:5/23/2015)... 23, 2015 Dr. David Benvenuti, an experienced ... posted a new article to his website that ... Dr Benvenuti explained in the fascinating blog, he has ... their earlobes. , Known as “gauging,” the technique involves placing ... Dr. Benvenuti said will eventually stretch the holes out to ...
(Date:5/23/2015)... With the implementation of the Affordable ... increasingly difficult to provide their employees with a viable ... insurance for employees stand to face strict penalties. Never ... part of a business’s success or failure. In an ... USA Doctors has created a varying level of less ...
(Date:5/23/2015)... New York, NY (PRWEB) May 23, 2015 ... (CareFirst) announced that, “the company has been the ... discovered as a part of the company’s ongoing Information ... cyberattacks on health insurers.” , The most notable ... this year when Anthem Inc., the nation’s second largest ...
(Date:5/23/2015)... CO (PRWEB) May 23, 2015 On May ... in MuckFest. The event was a 5k mud obstacle run ... more than 2 million people worldwide, and the reason we ... community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred ... Multiple Sclerosis Society.” , The event was not only attended ...
(Date:5/23/2015)... 23, 2015 Manufacturers are now required to ... (HSPF) of 8.2. Experts in the field agree that the ... , The HSPF score is what miles per gallon is ... the unit. Although the minimum HSPF score has been raised ... an HSPF score north of 12. Indeed, the regulation was ...
Breaking Medicine News(10 mins):Health News:Dr. Benvenuti, a Plastic Surgeon in Newport Beach, CA, Posts New Article about Repairing Ear Gauges 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... cancer (CRC) is the third leading cause of cancer ... of people who need CRC screening receive it. The ... patients about the importance of screening and to encourage ... CRC. Recognizing that those without insurance have ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... risk, but elderly women are too, study finds , THURSDAY, ... cause of shoulder dislocation, and young males have the highest ... shows. , Researchers studied 8,940 shoulder dislocations treated at 100 ... 2006 and found that the overall incidence rate was 23.9 ...
... ... MD, MPH, to determine whether they are allergic to penicillin. In years past, this was ... new product called Pre-Pen in his office, and is available for testing. , ... (PRWEB) March 4, 2010 -- Patients with ...
... ... ... , ... , , ...
... ... ... ... ...
Cached Medicine News:Health News:Physicians come together on National Colorectal Cancer Awareness and Screening Day 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Shoulder Dislocations a Sports Hazard 2Health News:New Allergy Testing Available for Patients Allergic to Penicillin: Determining the Presence of Penicillin Allergy is Essential to Patient Care 2Health News:Cymetrix Board Member Recognized for Enhancing the Growth and Operations of the Companies He Advises 2Health News:Cymetrix Board Member Recognized for Enhancing the Growth and Operations of the Companies He Advises 3Health News:Cymetrix Board Member Recognized for Enhancing the Growth and Operations of the Companies He Advises 4Health News:Thyroid Disease: The Hidden Epidemic 2Health News:Thyroid Disease: The Hidden Epidemic 3Health News:Thyroid Disease: The Hidden Epidemic 4
... The Johns Hopkins University Dermatology, ... Laboratory is a federally-(Clinical Laboratory Improvement ... that began operation in 1982. Its ... quality diagnostic allergy and immunology testing ...
... a national reference laboratory and a ... offers an extensive test menu of ... in clinical and anatomic pathology. Owned ... Laboratories clients include university teaching hospitals ...
Sharp tipped scissors angled 135 from the shaft with a horizontal cutting action. For cutting in the plane parallel to the retina and cutting membranes adherent to the retinal surface (delamination)....
Disposable Microscissors: Horizontal, Straight...
Medicine Products: